English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/187475
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorValdecantos, M. P.es_ES
dc.contributor.authorRuiz, Lauraes_ES
dc.contributor.authorPardo, Virginiaes_ES
dc.contributor.authorCastro-Sánchez, Luises_ES
dc.contributor.authorGarcía-Monzón, Carmeloes_ES
dc.contributor.authorLanzón, Borjaes_ES
dc.contributor.authorRupérez, Francisco J.es_ES
dc.contributor.authorBarbas, Corales_ES
dc.contributor.authorNaylor, Jaquelinees_ES
dc.contributor.authorTrevaskis, James L.es_ES
dc.contributor.authorGrimsby, J.es_ES
dc.contributor.authorRondinone, Cristina M.es_ES
dc.contributor.authorValverde, Ángela M.es_ES
dc.date.accessioned2019-08-02T09:00:41Z-
dc.date.available2019-08-02T09:00:41Z-
dc.date.issued2018-
dc.identifier.citationScientific Reports 8: 16461 (2018)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/187475-
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is associated with post-operative liver failure (PLF) and impaired liver regeneration. We investigated the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist on NAFLD, PLF and liver regeneration in mice fed chow diet or methionine/choline-deficient diet (MCD) or high fat diet (HFD). Fc-GLP-1 decreased transaminases, reduced intrahepatic triglycerides (TG) and improved MCD-induced liver dysfuction. Macrophage/Kupffer cell-related markers were also reduced although Fc-GLP-1 increased expression of genes related to natural killer (NK), cytotoxic T lymphocytes and hepatic stellate cell (HSC) activation. After partial hepatectomy (PH), survival rates increased in mice receiving Fc-GLP-1 on chow or MCD diet. However, the benefit of Fc-GLP-1 on NASH-like features was attenuated 2 weeks post-PH and liver mass restoration was not improved. At this time-period, markers of NK cells and cytotoxic T lymphocytes were further elevated in Fc-GLP-1 treated mice. Increased HSC related gene expression in livers was observed together with decreased retinyl ester content and increased retinal and retinoic acid, reflecting HSC activation. Similar effects were found in mice fed HFD receiving Fc-GLP-1. Our results shed light on the differential effects of a long-acting GLP-1R agonist in improving NAFLD and PLF, but not enhancing liver regeneration in mice.es_ES
dc.description.sponsorshipThis work was supported by grants SAF2015-65267-R (MINECO, Spain), S2017/BMD-3684 MOIR2-CM (Comunidad de Madrid, Spain), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”), European Foundation for the Study of Diabetes (EFSD) and H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement Number 721236) (European Commission) to A.M.V. Financial support was also received from MedImmune (MA-416191) as a research agreement with the Instituto de Investigaciones Biomedicas Alberto Sols.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.relationMINECO/ICTi2013-2016/SAF2015-65267-Res_ES
dc.relationS2017/BMD-3684/MOIR2-CMes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/721236es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.titleDifferential effects of a glucagon-like peptide 1 receptor agonist in non-alcoholic fatty liver disease and in response to hepatectomyes_ES
dc.typeartículoes_ES
dc.identifier.doi10.1038/s41598-018-33949-z-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-018-33949-zes_ES
dc.identifier.e-issn2045-2322-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderComunidad de Madrides_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderCSIC-UAM - Instituto de Investigaciones Biomédicas Alberto Sols (IIBM)es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderEuropean Foundation for the Study of Diabeteses_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100001648es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100012818es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.contributor.orcidCastro-Sánchez, Luis [0000-0002-7761-0136]es_ES
dc.contributor.orcidTrevaskis, James L. [0000-0002-5356-6118]es_ES
dc.identifier.pmid30405191-
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
differhepate.pdf8,35 MBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.